AbSci Corp (ABSI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABSI POWR Grades
- ABSI scores best on the Growth dimension, with a Growth rank ahead of 55% of US stocks.
- The strongest trend for ABSI is in Growth, which has been heading up over the past 177 days.
- ABSI's current lowest rank is in the Quality metric (where it is better than 4.1% of US stocks).
ABSI Stock Summary
- ABSI's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
- ABSCI CORP's stock had its IPO on July 22, 2021, making it an older stock than just 3.21% of US equities in our set.
- ABSI's price/sales ratio is 54.04; that's higher than the P/S ratio of 96.42% of US stocks.
- If you're looking for stocks that are quantitatively similar to ABSCI CORP, a group of peers worth examining would be GNTX, APLS, FOLD, LXRX, and MIRM.
- To check out ABSCI CORP's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001672688.
ABSI Valuation Summary
- ABSI's price/sales ratio is 44; this is 762.75% higher than that of the median Healthcare stock.
- ABSI's price/sales ratio has moved down 364.2 over the prior 18 months.
Below are key valuation metrics over time for ABSI.
ABSI Stock Price Chart Interactive Chart >
ABSI Price/Volume Stats
|Current price||$3.26||52-week high||$9.68|
|Prev. close||$3.30||52-week low||$1.94|
|Day high||$3.44||Avg. volume||461,622|
|50-day MA||$2.55||Dividend yield||N/A|
|200-day MA||$3.55||Market Cap||301.21M|
AbSci Corp (ABSI) Company Bio
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Most Popular Stories View All
ABSI Latest News Stream
|Loading, please wait...|
ABSI Latest Social Stream
View Full ABSI Social Stream
Latest ABSI News From Around the Web
Below are the latest news stories about ABSCI CORP that investors may wish to consider to help them evaluate ABSI as an investment opportunity.
In this article, we will discuss the 10 penny stocks that will make you a millionaire. If you want to explore similar stocks, you can also take a look at 5 Penny Stocks That Will Make You A Millionaire. Penny stocks can be an attractive option for investors looking to get in on the stock […]
The discovery could reduce the time it takes to get new drug candidates to clinic to 18-24 months from six years.
This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully de novo antibody design and Absci’s vision to deliver breakthrough therapeutics at the click of a button, for everyone. VANCOUVER, Wash. and NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company,
Absci Corporation (NASDAQ:ABSI) marked $2.26 per share on Tuesday, up from a previous closing price of $2.10. While Absci Corporation has overperformed by 7.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABSI fell by -72.44%, with highs and lows ranging from $9.68 to $1.94, whereas […]
It's not a secret that every investor will make bad investments, from time to time. But it should be a priority to...
ABSI Price Returns